• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

计算药物多靶性在现代药物发现中的最新概述。

An up-to-date overview of computational polypharmacology in modern drug discovery.

机构信息

Intelligent Molecular Discovery Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.

MD Anderson UTHealth Graduate School of Biomedical Sciences , Houston, TX, USA.

出版信息

Expert Opin Drug Discov. 2020 Sep;15(9):1025-1044. doi: 10.1080/17460441.2020.1767063. Epub 2020 May 26.

DOI:10.1080/17460441.2020.1767063
PMID:32452701
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7415563/
Abstract

INTRODUCTION

In recent years, computational polypharmacology has gained significant attention to study the promiscuous nature of drugs. Despite tremendous challenges, community-wide efforts have led to a variety of novel approaches for predicting drug polypharmacology. In particular, some rapid advances using machine learning and artificial intelligence have been reported with great success.

AREAS COVERED

In this article, the authors provide a comprehensive update on the current state-of-the-art polypharmacology approaches and their applications, focusing on those reports published after our 2017 review article. The authors particularly discuss some novel, groundbreaking concepts, and methods that have been developed recently and applied to drug polypharmacology studies.

EXPERT OPINION

Polypharmacology is evolving and novel concepts are being introduced to counter the current challenges in the field. However, major hurdles remain including incompleteness of high-quality experimental data, lack of and assays to characterize multi-targeting agents, shortage of robust computational methods, and challenges to identify the best target combinations and design effective multi-targeting agents. Fortunately, numerous national/international efforts including multi-omics and artificial intelligence initiatives as well as most recent collaborations on addressing the COVID-19 pandemic have shown significant promise to propel the field of polypharmacology forward.

摘要

简介

近年来,计算药物多靶性已经引起了人们的广泛关注,以研究药物的混杂性质。尽管面临巨大挑战,但全行业的努力已经促成了多种新型方法来预测药物多靶性。特别是,一些使用机器学习和人工智能的快速进展已经取得了巨大的成功。

涵盖领域

本文作者全面介绍了当前药物多靶性研究的最新进展及其应用,重点介绍了自 2017 年我们的综述文章发表以来的报告。作者特别讨论了一些最近开发并应用于药物多靶性研究的新颖、开创性概念和方法。

专家意见

药物多靶性正在发展,新的概念正在被引入以应对该领域当前的挑战。然而,仍然存在重大障碍,包括高质量实验数据的不完整性、缺乏用于表征多靶标药物的测定法和 assays、缺乏稳健的计算方法,以及难以确定最佳的靶标组合和设计有效的多靶标药物。幸运的是,许多国家/国际的努力,包括多组学和人工智能计划,以及最近为解决 COVID-19 大流行而开展的合作,都显示出了巨大的潜力,可以推动药物多靶性领域向前发展。

相似文献

1
An up-to-date overview of computational polypharmacology in modern drug discovery.计算药物多靶性在现代药物发现中的最新概述。
Expert Opin Drug Discov. 2020 Sep;15(9):1025-1044. doi: 10.1080/17460441.2020.1767063. Epub 2020 May 26.
2
Computational polypharmacology: a new paradigm for drug discovery.计算多药理学:药物发现的新范式。
Expert Opin Drug Discov. 2017 Mar;12(3):279-291. doi: 10.1080/17460441.2017.1280024. Epub 2017 Jan 23.
3
Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery.多药理学预测:全面预测小分子选择性以降低药物发现风险的漫漫征途。
Expert Opin Drug Discov. 2024 Sep;19(9):1043-1069. doi: 10.1080/17460441.2024.2376643. Epub 2024 Jul 14.
4
Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery.提高多靶点药物发现中多药联用的疗效-安全性平衡。
Expert Opin Drug Discov. 2018 Feb;13(2):179-192. doi: 10.1080/17460441.2018.1413089. Epub 2017 Dec 12.
5
Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective.药物发现中的多药理学:从系统药理学角度的综述
Curr Pharm Des. 2016;22(21):3171-81. doi: 10.2174/1381612822666160224142812.
6
In silico methods to address polypharmacology: current status, applications and future perspectives.用于解决多药理学问题的计算机模拟方法:现状、应用及未来展望。
Drug Discov Today. 2016 Feb;21(2):288-98. doi: 10.1016/j.drudis.2015.12.007. Epub 2015 Dec 29.
7
Computational tools for polypharmacology and repurposing.多靶标药物和再利用的计算工具。
Future Med Chem. 2011 Jun;3(8):961-8. doi: 10.4155/fmc.11.62.
8
AI for targeted polypharmacology: The next frontier in drug discovery.人工智能在靶向多药理学中的应用:药物发现的下一个前沿领域。
Curr Opin Struct Biol. 2024 Feb;84:102771. doi: 10.1016/j.sbi.2023.102771. Epub 2024 Jan 11.
9
Data structures for computational compound promiscuity analysis and exemplary applications to inhibitors of the human kinome.计算化合物混杂分析的数据结构及其在人类激酶组抑制剂中的应用实例
J Comput Aided Mol Des. 2020 Jan;34(1):1-10. doi: 10.1007/s10822-019-00266-0. Epub 2019 Dec 2.
10
Web-Based Tools for Polypharmacology Prediction.用于多药理学预测的基于网络的工具。
Methods Mol Biol. 2019;1888:255-272. doi: 10.1007/978-1-4939-8891-4_15.

引用本文的文献

1
AI-Driven Polypharmacology in Small-Molecule Drug Discovery.小分子药物发现中的人工智能驱动多药理学
Int J Mol Sci. 2025 Jul 21;26(14):6996. doi: 10.3390/ijms26146996.
2
Trends and Pitfalls in the Progress of Network Pharmacology Research on Natural Products.天然产物网络药理学研究进展中的趋势与陷阱
Pharmaceuticals (Basel). 2025 Apr 7;18(4):538. doi: 10.3390/ph18040538.
3
Better understanding the phenotypic effects of drugs through shared targets in genetic disease networks.通过遗传疾病网络中的共享靶点更好地理解药物的表型效应。

本文引用的文献

1
Germline and Somatic Smoothened Mutations in Non-Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib.非小细胞肺癌中的种系和体细胞平滑肌瘤突变可能对刺猬信号通路抑制剂维莫德吉有反应。
JCO Precis Oncol. 2017 Nov;1:1-10. doi: 10.1200/PO.17.00149.
2
Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2.多中心关于儿童 2019 冠状病毒病/严重急性呼吸综合征冠状病毒 2 抗病毒药物使用的初始指导意见
J Pediatric Infect Dis Soc. 2020 Dec 31;9(6):701-715. doi: 10.1093/jpids/piaa045.
3
Coronavirus puts drug repurposing on the fast track.
Front Pharmacol. 2025 Jan 22;15:1470931. doi: 10.3389/fphar.2024.1470931. eCollection 2024.
4
Bioinformatics and molecular biology tools for diagnosis, prevention, treatment and prognosis of COVID-19.用于COVID-19诊断、预防、治疗和预后的生物信息学与分子生物学工具
Heliyon. 2024 Jul 11;10(14):e34393. doi: 10.1016/j.heliyon.2024.e34393. eCollection 2024 Jul 30.
5
Epoxy-a-lapachone in nanosystem: a prototype drug for leishmaniasis assessed in the binomial BALB/c - Leishmania (Leishmania) amazonensis.纳米体系中环氧化拉帕醌:用于利什曼病的原型药物,在二项式 BALB/c-利什曼原虫(利什曼原虫)亚马逊亚种中进行评估。
Mem Inst Oswaldo Cruz. 2024 Oct 28;119:e240115. doi: 10.1590/0074-02760240115. eCollection 2024.
6
AI in Clinical Trials and Drug Development: Challenges and Potential Advancements.人工智能在临床试验和药物研发中的挑战与潜在进展
Curr Drug Discov Technol. 2024 Oct 28. doi: 10.2174/0115701638314252241016165345.
7
VirtuousPocketome: a computational tool for screening protein-ligand complexes to identify similar binding sites.VirtuousPocketome:一种用于筛选蛋白-配体复合物以识别相似结合位点的计算工具。
Sci Rep. 2024 Mar 15;14(1):6296. doi: 10.1038/s41598-024-56893-7.
8
Integrating Artificial Intelligence for Drug Discovery in the Context of Revolutionizing Drug Delivery.在药物递送变革的背景下整合人工智能用于药物发现。
Life (Basel). 2024 Feb 7;14(2):233. doi: 10.3390/life14020233.
9
Challenges in phytotherapy research.植物疗法研究中的挑战。
Front Pharmacol. 2023 May 31;14:1199516. doi: 10.3389/fphar.2023.1199516. eCollection 2023.
10
Polypharmacology: promises and new drugs in 2022.多靶标药物:2022 年的承诺与新药
Pharmacol Rep. 2023 Aug;75(4):755-770. doi: 10.1007/s43440-023-00501-4. Epub 2023 Jun 6.
冠状病毒使药物重新利用走上快车道。
Nat Biotechnol. 2020 Apr;38(4):379-381. doi: 10.1038/d41587-020-00003-1.
4
First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma.SLAMF7/CS1 靶向抗体药物偶联物 ABBV-838 治疗复发/难治性多发性骨髓瘤患者的首次人体 I 期研究。
Clin Cancer Res. 2020 May 15;26(10):2308-2317. doi: 10.1158/1078-0432.CCR-19-1431. Epub 2020 Jan 22.
5
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.蛋白水解靶向嵌合体作为治疗方法和生物发现工具。
Cell. 2020 Apr 2;181(1):102-114. doi: 10.1016/j.cell.2019.11.031. Epub 2020 Jan 16.
6
Improved protein structure prediction using potentials from deep learning.利用深度学习势进行蛋白质结构预测的改进。
Nature. 2020 Jan;577(7792):706-710. doi: 10.1038/s41586-019-1923-7. Epub 2020 Jan 15.
7
Multi-target dopamine D3 receptor modulators: Actionable knowledge for drug design from molecular dynamics and machine learning.多靶点多巴胺 D3 受体调节剂:来自分子动力学和机器学习的药物设计可操作知识。
Eur J Med Chem. 2020 Feb 15;188:111975. doi: 10.1016/j.ejmech.2019.111975. Epub 2019 Dec 23.
8
Exploring Targeted Degradation Strategy for Oncogenic KRAS.探索致癌 KRAS 的靶向降解策略。
Cell Chem Biol. 2020 Jan 16;27(1):19-31.e6. doi: 10.1016/j.chembiol.2019.12.006. Epub 2019 Dec 26.
9
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.一项抗体药物偶联物 Brentuximab Vedotin 联合再诱导化疗治疗 CD30 表达的复发/难治性急性髓系白血病患者的 1 期研究。
Cancer. 2020 Mar 15;126(6):1264-1273. doi: 10.1002/cncr.32657. Epub 2019 Dec 20.
10
Engineering strategies to overcome the current roadblocks in CAR T cell therapy.克服 CAR T 细胞疗法当前障碍的工程策略。
Nat Rev Clin Oncol. 2020 Mar;17(3):147-167. doi: 10.1038/s41571-019-0297-y. Epub 2019 Dec 17.